10x Genomics is upgraded from 'Sell' to 'Hold' after a significant price drop and improved profitability, aided by a favorable Bruker settlement. TXG's Q2 profitability is driven by $68 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results